Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...

Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Terns Pharmaceuticals (TERN – Research Report), with ...

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and ...

On The Readout LOUD this week, STAT reporters discuss the FDA's staff cuts, how next-gen drugs may lead to too much weight ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced that it has entered into a licensing agreement with Roche (OTC:RHHBY) related to its lead gene therapy candidate, SRP-9001,... Investors in Solid ...

Candel Therapeutics Inc. shares gained momentum as Wall Street analysts highlighted the potential of its lead cancer drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...